KR20180014834A - 카보플라틴을 함유하는 조성물 및 용도 - Google Patents
카보플라틴을 함유하는 조성물 및 용도 Download PDFInfo
- Publication number
- KR20180014834A KR20180014834A KR1020187001614A KR20187001614A KR20180014834A KR 20180014834 A KR20180014834 A KR 20180014834A KR 1020187001614 A KR1020187001614 A KR 1020187001614A KR 20187001614 A KR20187001614 A KR 20187001614A KR 20180014834 A KR20180014834 A KR 20180014834A
- Authority
- KR
- South Korea
- Prior art keywords
- dcp
- subject
- pharmaceutical composition
- leukemia
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004562 carboplatin Drugs 0.000 title description 30
- 239000000203 mixture Substances 0.000 title description 8
- 190000008236 carboplatin Chemical compound 0.000 title 1
- 201000001441 melanoma Diseases 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 40
- 208000032839 leukemia Diseases 0.000 claims abstract description 31
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 25
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract description 20
- 210000003734 kidney Anatomy 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 75
- 230000037396 body weight Effects 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 21
- 229960002949 fluorouracil Drugs 0.000 claims description 21
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 17
- 230000003211 malignant effect Effects 0.000 claims description 16
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 9
- 210000003292 kidney cell Anatomy 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 6
- 244000186892 Aloe vera Species 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- 235000011399 aloe vera Nutrition 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 6
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 6
- 229940109262 curcumin Drugs 0.000 claims description 6
- 235000012754 curcumin Nutrition 0.000 claims description 6
- 239000004148 curcumin Substances 0.000 claims description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000003969 glutathione Nutrition 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 208000025113 myeloid leukemia Diseases 0.000 claims description 4
- 201000010174 renal carcinoma Diseases 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 210000001167 myeloblast Anatomy 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 45
- 230000002265 prevention Effects 0.000 abstract description 19
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 27
- 238000012360 testing method Methods 0.000 description 16
- 230000003833 cell viability Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 13
- 229960000485 methotrexate Drugs 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 9
- 229960005420 etoposide Drugs 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100020870 La-related protein 6 Human genes 0.000 description 5
- 108050008265 La-related protein 6 Proteins 0.000 description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
- 229960001467 bortezomib Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 231100000956 nontoxicity Toxicity 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- AENCTOAEVOLYHR-UHFFFAOYSA-N azanide cyclobutane-1,1-dicarboxylic acid platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.OC(=O)C1(C(O)=O)CCC1 AENCTOAEVOLYHR-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 201000000292 clear cell sarcoma Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 201000010276 collecting duct carcinoma Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-L cyclobutane-1,1-dicarboxylate(2-) Chemical compound [O-]C(=O)C1(C([O-])=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-L 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 201000003731 mucosal melanoma Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000003233 renal Wilms' tumor Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001982 uveitic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182124P | 2015-06-19 | 2015-06-19 | |
| US62/182,124 | 2015-06-19 | ||
| PCT/US2016/038333 WO2016205782A1 (en) | 2015-06-19 | 2016-06-20 | Composition containing carboplatin and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180014834A true KR20180014834A (ko) | 2018-02-09 |
Family
ID=57546650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187001614A Ceased KR20180014834A (ko) | 2015-06-19 | 2016-06-20 | 카보플라틴을 함유하는 조성물 및 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10980768B2 (enExample) |
| EP (1) | EP3297440A4 (enExample) |
| JP (1) | JP2018517759A (enExample) |
| KR (1) | KR20180014834A (enExample) |
| CN (1) | CN108697093A (enExample) |
| AU (1) | AU2016279096B2 (enExample) |
| BR (1) | BR112017027277A2 (enExample) |
| CA (1) | CA2988989A1 (enExample) |
| WO (1) | WO2016205782A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180008594A (ko) | 2015-05-18 | 2018-01-24 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 및 그의 용도 |
| JP6768716B2 (ja) | 2015-06-19 | 2020-10-14 | シン−ナット プロダクツ エンタープライズ エルエルシー | カルボプラチンベースの共結晶の医薬組成物及びその用途 |
| EP3297440A4 (en) | 2015-06-19 | 2019-04-10 | Syn-Nat Products Enterprise LLC | COMPOSITION WITH CARBOPLATIN AND USE |
| KR20180021805A (ko) | 2015-06-25 | 2018-03-05 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 조성물 및 이의 용도 |
| MX2020005310A (es) * | 2017-11-21 | 2020-10-08 | Medoncare Pharmaceutical Co Ltd | Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo. |
| CN108884119A (zh) * | 2018-02-22 | 2018-11-23 | 昆明贵研药业有限公司 | 一种双二羧酸二氨络铂(ii)衍生物的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922689A (en) | 1995-09-11 | 1999-07-13 | Unitech Pharmaceuticals, Inc. | Cisplatin analogs for cancer treatment |
| US6297245B1 (en) | 1998-08-04 | 2001-10-02 | Unitech Pharmaceuticals | Cisplatin and folic acid administered to treat breast cancer |
| KR100317473B1 (ko) | 1999-05-11 | 2001-12-22 | 이계호 | 신규의 백금(ｉｖ)착제 및 그 제조방법 |
| CN1121380C (zh) | 2000-03-03 | 2003-09-17 | 北京兴大豪斯科技有限公司 | 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物 |
| CN1314357A (zh) * | 2000-03-16 | 2001-09-26 | 杨旭清 | 双环酸铂抗癌药 |
| AUPQ641100A0 (en) | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| ATE390921T1 (de) * | 2001-05-31 | 2008-04-15 | Univ Hong Kong Chinese | Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung |
| US7259270B2 (en) | 2001-11-30 | 2007-08-21 | Jingzun Wang | Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EA200500234A1 (ru) | 2002-08-19 | 2005-08-25 | Пфайзер Продактс Инк. | Комбинированная терапия гиперпролиферативных болезней |
| CA2535762A1 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
| EP1845974A1 (en) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CN100391437C (zh) * | 2005-09-12 | 2008-06-04 | 重庆医科大学附属第二医院 | 抗急性髓性白血病的gm-csf靶向药物脂质体及制备方法 |
| KR20080096682A (ko) | 2006-01-30 | 2008-10-31 | 플라트코 테크놀로지스 (프로프라이어터리) 리미티드 | 백금(ⅱ) 착물의 제조법 |
| CN1857221A (zh) * | 2006-04-14 | 2006-11-08 | 济南帅华医药科技有限公司 | 一种同载铂类化合物及其增效剂的抗癌缓释剂 |
| JP2009545601A (ja) * | 2006-08-02 | 2009-12-24 | サネシス ファーマシューティカルズ， インコーポレイテッド | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用 |
| BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
| CZ302618B6 (cs) | 2009-09-10 | 2011-08-03 | Univerzita Palackého | Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii |
| US20110287110A1 (en) * | 2010-04-23 | 2011-11-24 | Mark Wesley Dewhirst | Combination cancer treatment |
| ES2694582T3 (es) * | 2011-01-31 | 2018-12-21 | Lucolas-M.D. Ltd. | Combinaciones de inhibidores de aromatasa y antioxidantes |
| CN102924528B (zh) * | 2012-10-29 | 2015-04-15 | 东南大学 | 抗肿瘤二价铂配合物以及该配合物和其配体的制备方法 |
| EP2924044B1 (en) * | 2012-11-17 | 2018-10-31 | Beijing Shuobai Pharmaceutical Co., LTD | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
| CN103494838B (zh) | 2013-09-30 | 2016-05-11 | 武汉大学 | 一种化疗药物组合物 |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| CN107167482B (zh) * | 2014-08-13 | 2020-07-14 | 北京默加农生物技术发展有限公司 | 一种以双环铂为有效成分的药物的检测方法 |
| CN104127402B (zh) * | 2014-08-15 | 2019-08-30 | 北京默加农生物技术发展有限公司 | 双环铂在制备抗病毒药物和抗菌药物中的应用 |
| CN104693245A (zh) | 2015-03-13 | 2015-06-10 | 卓越同达医药科技开发（苏州）有限公司 | 超分子抗癌药物双环铂的制备方法 |
| CN106132408B (zh) | 2015-04-10 | 2018-02-13 | 新纳特产品公司 | 一种双环铂的制备方法 |
| CN107530309A (zh) | 2015-04-22 | 2018-01-02 | 新纳特产品公司 | 共晶组合物及其药物用途 |
| KR20180008594A (ko) | 2015-05-18 | 2018-01-24 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 및 그의 용도 |
| JP6768716B2 (ja) | 2015-06-19 | 2020-10-14 | シン−ナット プロダクツ エンタープライズ エルエルシー | カルボプラチンベースの共結晶の医薬組成物及びその用途 |
| EP3297440A4 (en) | 2015-06-19 | 2019-04-10 | Syn-Nat Products Enterprise LLC | COMPOSITION WITH CARBOPLATIN AND USE |
| KR20180021805A (ko) | 2015-06-25 | 2018-03-05 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 조성물 및 이의 용도 |
-
2016
- 2016-06-20 EP EP16812606.8A patent/EP3297440A4/en not_active Withdrawn
- 2016-06-20 WO PCT/US2016/038333 patent/WO2016205782A1/en not_active Ceased
- 2016-06-20 BR BR112017027277A patent/BR112017027277A2/pt not_active IP Right Cessation
- 2016-06-20 KR KR1020187001614A patent/KR20180014834A/ko not_active Ceased
- 2016-06-20 US US15/736,170 patent/US10980768B2/en active Active
- 2016-06-20 JP JP2017566021A patent/JP2018517759A/ja active Pending
- 2016-06-20 CA CA2988989A patent/CA2988989A1/en not_active Abandoned
- 2016-06-20 AU AU2016279096A patent/AU2016279096B2/en not_active Ceased
- 2016-06-20 CN CN201680035788.7A patent/CN108697093A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3297440A1 (en) | 2018-03-28 |
| JP2018517759A (ja) | 2018-07-05 |
| AU2016279096A1 (en) | 2018-01-04 |
| AU2016279096B2 (en) | 2021-01-07 |
| BR112017027277A2 (pt) | 2018-09-04 |
| US10980768B2 (en) | 2021-04-20 |
| CN108697093A (zh) | 2018-10-23 |
| EP3297440A4 (en) | 2019-04-10 |
| WO2016205782A1 (en) | 2016-12-22 |
| CA2988989A1 (en) | 2016-12-22 |
| US20180169055A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| Zou et al. | Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway | |
| AU2016279096B2 (en) | Composition containing carboplatin and use | |
| HK1221638A1 (zh) | 使用辅酶q10联合疗法治疗癌症 | |
| EP3429614B1 (en) | Method of treating triple negative breast cancer | |
| WO2010125462A2 (en) | Pentamidine combinations for treating cancer | |
| He et al. | Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy | |
| WO2022228323A1 (zh) | Ly3009120在制备治疗骨髓增殖性肿瘤的药物中的应用 | |
| KR20160135230A (ko) | 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도 | |
| CN115702891A (zh) | 和厚朴酚在制备用于治疗脑膜瘤的药物中的用途 | |
| WO2015172712A1 (zh) | 维生素c与抗肿瘤药物协同作用的注射用药物组合物 | |
| Alexandre et al. | Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients | |
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer | |
| TWI849001B (zh) | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 | |
| JP6234553B2 (ja) | 抗癌剤および副作用軽減剤 | |
| Zang et al. | Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer | |
| CN113456643B (zh) | 一种含普那布林的药物组合及其应用 | |
| CN101167741A (zh) | 莱菔硫烷和铂类药的抗癌联合制剂 | |
| EP3641775A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof | |
| CN107198685B (zh) | 一种治疗肾细胞癌的药物组合物及应用 | |
| WO2013169390A1 (en) | Zeaxanthin for tumor treatment | |
| JP6243850B2 (ja) | 抗がん剤による末梢神経障害の予防、治療、または軽減剤 | |
| RU2818453C2 (ru) | Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции | |
| CN110893189A (zh) | 阿帕替尼与依托泊苷联合在制备治疗肺癌的药物中的用途 | |
| CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180117 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210615 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230403 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230901 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230403 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |